IncobotulinumtoxinA use in aesthetic indications in daily practice: a European multicenter, noninterventional, retrospective study

Tatjana Pavicic, Welf Prager, Markus Klöppel, Simon Ravichandran, Olivier Galatoire, Tatjana Pavicic, Welf Prager, Markus Klöppel, Simon Ravichandran, Olivier Galatoire

Abstract

Purpose: To characterize utilization patterns and treatment satisfaction with incobotulinumtoxinA for aesthetic indications and assess adherence to the Summary of Product Characteristics.

Patients and methods: Data were collected retrospectively from physicians in Germany, France, and the UK regarding patients (n=638) treated with incobotulinumtoxinA for aesthetic indications. Data on indication, treatment interval, dose injected, physician and patient satisfaction, and adverse drug reactions were recorded according to routine daily practice.

Results: Most patients (76.0%) received incobotulinumtoxinA for glabellar frown lines (GFL) and were given doses of ≤20 U. The majority of treatment intervals were 5 months or longer. Overall, 64.1% of patients were treated for off-label indications, sometimes in combination with treatment for GFL. The most frequently treated off-label indications were horizontal forehead lines (38.6%) and/or crow's feet (CF; 31.7%); for CF, >95% of injected doses were ≤24 U. In Germany, a smaller proportion of patients were given incobotulinumtoxinA treatment for CF (27.6%), compared with France (40.4%) and the UK (33.2%), although country-specific differences were less prominent when treatment cycle data for CF were examined. Treatment satisfaction among physicians and patients (overall, and for GFL specifically) was very high, with excellent tolerability and only one mild adverse drug reaction reported.

Conclusion: In daily practice, incobotulinumtoxinA is mainly used for GFL; however, its use for CF and horizontal forehead lines (often in combination with GFL) is relatively common. Treatment satisfaction across aesthetic indications is high, and incobotulinumtoxinA is well tolerated, with time intervals of 5 months or longer between injections in the majority of cases. When considering factors such as dose and treatment interval, adherence to the Summary of Product Characteristics when treating GFL in daily practice is good. These results support previous reports that incobotulinumtoxinA is an effective treatment for GFL, with an excellent safety profile. Furthermore, incobotulinumtoxinA may display efficacy and tolerability in other indications.

Keywords: NT 201; Xeomin®/Xeomeen®/Bocouture®/XEOMIN Cosmetic™; crow’s feet; daily practice; free from complexing proteins; glabellar frown lines; incobotulinumtoxinA; retrospective.

Figures

Figure 1
Figure 1
Time intervals between incobotulinumtoxinA injections to treat glabellar frown lines. Notes: Interval length was calculated as: date of subsequent treatment minus the date of preceding treatment. It could only be calculated for completed treatment cycles, ie, where the date of the following injection was given. This was not the case for the most recent treatment cycle with each patient. No further data are missing.
Figure 2
Figure 2
Dose of incobotulinumtoxinA injected to treat (A) glabellar frown lines and (B) crow’s feet. Notes: n=1,004 for glabellar frown lines, as data were missing for one patient; n=292 for crow’s feet.
Figure 3
Figure 3
Physician satisfaction with incobotulinumtoxinA treatment cycles for glabellar frown lines, separated by injected dose. Note: n=556.
Figure 4
Figure 4
Patient satisfaction with incobotulinumtoxinA treatment for glabellar frown lines, separated by injected dose.

References

    1. Bocouture® Summary of Product Characteristics. Germany: Merz Pharmaceuticals GmbH; 2014.
    1. Wenzel R, Jones D, Borrego JA. Comparing two botulinum toxin type A formulations using manufacturers’ product summaries. J Clin Pharm Ther. 2007;32(4):387–402.
    1. Carruthers J, Fournier N, Kerscher M, Ruiz-Avila J, Trindade de Almeida AR, Kaeuper G. The convergence of medicine and neurotoxins: a focus on botulinum toxin type A and its application in aesthetic medicine – a global, evidence-based botulinum toxin consensus education initiative: part II: incorporating botulinum toxin into aesthetic clinical practice. Dermatol Surg. 2013;39(3 Pt 2):510–525.
    1. Vistabel®. Summary of Product Characteristics. Irvine, CA, USA: Allergan, Inc; 2013.
    1. Alimohammadi M, Andersson M, Punga AR. Correlation of botulinum toxin dose with neurophysiological parameters of efficacy and safety in the glabellar muscles: a double-blind, placebo-controlled, randomized study. Acta Derm Venereol. 2014;94:32–37.
    1. Dressler D, Benecke R. Pharmacology of therapeutic botulinum toxin preparations. Disabil Rehabil. 2007;29(23):1761–1768.
    1. Carruthers JD, Carruthers JA. Treatment of glabellar frown lines with C. botulinum-A exotoxin. J Dermatol Surg Oncol. 1992;18(1):17–21.
    1. Frevert J. Content of botulinum neurotoxin in Botox®/Vistabel®, Dysport®/Azzalure®, and Xeomin®/Bocouture®. Drugs R D. 2010;10(2):67–73.
    1. Gubanova EI, Panova OS, Sanchez EA, Rodina MY, Starovatova PA. Efficacy and safety of incobotulinumtoxinA for the treatment of platysmal bands of the aging neck: an open-label, prospective pilot study. J Drugs Dermatol. 2013;12(12):1461–1466.
    1. Kane MA. Nonsurgical treatment of platysma bands with injection of botulinum toxin A revisited. Plast Reconstr Surg. 2003;112(Suppl 5):125S–126S.
    1. Lee JH, Park JH, Lee SK, et al. Efficacy and safety of incobotulinum toxin A in periocular rhytides and masseteric hypertrophy: side-by-side comparison with onabotulinum toxin A. J Dermatolog Treat. 2014;25(4):326–330.
    1. Oliveira de Morais O, Matos Reis-Filho E, Vilela Pereira L, Martins Gomes C, Alves G. Comparison of four botulinum neurotoxin type A preparations in the treatment of hyperdynamic forehead lines in men: a pilot study. J Drugs Dermatol. 2012;11(2):216–219.
    1. Prager W. Differential characteristics of incobotulinumtoxinA and its use in the management of glabellar frown lines. Clin Pharmacol. 2013;5:39–52.
    1. Carruthers JA, Lowe NJ, Menter MA, et al. A multicenter, double-blind, randomized, placebo-controlled study of the efficacy and safety of botulinum toxin type A in the treatment of glabellar lines. J Am Acad Dermatol. 2002;46(6):840–849.
    1. Carruthers JD, Lowe NJ, Menter MA, Gibson J, Eadie N. Double-blind, placebo-controlled study of the safety and efficacy of botulinum toxin type A for patients with glabellar lines. Plast Reconstr Surg. 2003;112(4):1089–1098.
    1. Carruthers A, Carruthers J, Coleman WP, 3rd, et al. Multicenter, randomized, phase III study of a single dose of incobotulinumtoxinA, free from complexing proteins, in the treatment of glabellar frown lines. Dermatol Surg. 2013;39(4):551–558.
    1. Hanke CW, Narins RS, Brandt F, et al. A randomized, placebo-controlled, double-blind phase III trial investigating the efficacy and safety of incobotulinumtoxinA in the treatment of glabellar frown lines using a stringent composite endpoint. Dermatol Surg. 2013;39(6):891–899.
    1. Sattler G, Callander M, Grablowitz D, et al. Noninferiority of incobotulinumtoxinA, free from complexing proteins, compared with another botulinum toxin type A in the treatment of glabellar frown lines. Dermatol Surg. 2010;36(Suppl 4):2146–2154.
    1. Prager W, Wissmüller E, Kollhorst B, Williams S, Zschocke I. Comparison of two botulinum toxin type A preparations for treating crow’s feet: a split-face, double-blind, proof-of-concept study. Dermatol Surg. 2010;36(Suppl 4):2155–2160.
    1. Muti G. Efficacy of incobotulinumtoxinA and onabotulinumtoxinA to treat crow’s feet; Summer Academy Meeting of the American Academy of Dermatology; August 6–10; 2014; Chicago, IL.
    1. Lorenc ZP, Kenkel JM, Fagien S, et al. Consensus panel’s assessment and recommendations on the use of 3 botulinum toxin type A products in facial aesthetics. Aesthet Surg J. 2013;33(Suppl 1):35S–40S.
    1. Poulain B, Trevidic P, Clave M, et al. Clinical equivalence of conventional onabotulinumtoxinA (900 KDa) and incobotulinumtoxinA (neurotoxin free from complexing proteins – 150 KDa): 2012 multidisciplinary French consensus in aesthetics. J Drugs Dermatol. 2013;12(12):1434–1446.
    1. Prager W, Bee EK, Havermann I, Zschocke I. Onset, longevity, and patient satisfaction with incobotulinumtoxinA for the treatment of glabellar frown lines: a single-arm, prospective clinical study. Clin Interv Aging. 2013;8:449–456.
    1. Rappl T, Parvizi D, Friedl H, et al. Onset and duration of effect of incobotulinumtoxinA, onabotulinumtoxinA, and abobotulinumtoxinA in the treatment of glabellar frown lines: a randomized, double-blind study. Clin Cosmet Investig Dermatol. 2013;6:211–219.
    1. Ascher B, Talarico S, Cassuto D, et al. International consensus recommendations on the aesthetic usage of botulinum toxin type A (Speywood Unit) – part I: upper facial wrinkles. J Eur Acad Dermatol Venereol. 2010;24(11):1278–1284.
    1. Prager W, Huber-Vorlander J, Taufig AZ, et al. Botulinum toxin type A treatment to the upper face: retrospective analysis of daily practice. Clin Cosmet Investig Dermatol. 2012;5:53–58.
    1. Ascher B, Zakine B, Kestemont P, Baspeyras M, Bougara A, Santini J. A multicenter, randomized, double-blind, placebo-controlled study of efficacy and safety of 3 doses of botulinum toxin A in the treatment of glabellar lines. J Am Acad Dermatol. 2004;51(2):223–233.
    1. Kane MA, Brandt F, Rohrich RJ, Narins RS, Monheit GD, Huber MB. Evaluation of variable-dose treatment with a new U.S. Botulinum Toxin Type A (Dysport) for correction of moderate to severe glabellar lines: results from a phase III, randomized, double-blind, placebo-controlled study. Plast Reconstr Surg. 2009;124(5):1619–1629.
    1. Carruthers A, Carruthers J. A single-center, dose-comparison, pilot study of botulinum neurotoxin type A in female patients with upper facial rhytids: safety and efficacy. J Am Acad Dermatol. 2009;60(6):972–979.
    1. Azzalure®. Summary of Product Characteristics. Hertfordshire, UK: Galderma (UK) Ltd; 2010.

Source: PubMed

Patrocinadores y Colaboradores

Condiciones médicas

Intervenciones de drogas

3
Suscribir